| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3582 | 2014 |
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ... Journal of clinical oncology 28 (6), 1061-1068, 2010 | 3107 | 2010 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1440 | 2019 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 822 | 2021 |
| Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ... The Lancet 395 (10236), 1547-1557, 2020 | 776 | 2020 |
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update CN Sternberg, RE Hawkins, J Wagstaff, P Salman, J Mardiak, CH Barrios, ... European journal of cancer 49 (6), 1287-1296, 2013 | 534 | 2013 |
| Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, ... Proceedings of the National Academy of Sciences 101 (29), 10697-10702, 2004 | 534 | 2004 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 530 | 2018 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 461 | 2020 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS de Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 408 | 2015 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 392 | 2020 |
| Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ... Journal of Clinical Oncology 28 (3), 475-480, 2010 | 362 | 2010 |
| Breast and prostate cancer: more similar than different GP Risbridger, ID Davis, SN Birrell, WD Tilley Nature Reviews Cancer 10 (3), 205-212, 2010 | 331 | 2010 |
| Tumor antigen expression in melanoma varies according to antigen and stage C Barrow, J Browning, D MacGregor, ID Davis, S Sturrock, AA Jungbluth, ... Clinical Cancer Research 12 (3), 764-771, 2006 | 324 | 2006 |
| Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial RJ Motzer, C Porta, NJ Vogelzang, CN Sternberg, C Szczylik, J Zolnierek, ... The Lancet Oncology 15 (3), 286-296, 2014 | 309 | 2014 |
| Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial A Kneebone, C Fraser-Browne, GM Duchesne, R Fisher, M Frydenberg, ... The Lancet Oncology 21 (10), 1331-1340, 2020 | 298 | 2020 |
| Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma S RAMDAVE, GW THOMAS, SU Berlangieri, DM Bolton, IAN Davis, ... The Journal of urology 166 (3), 825-830, 2001 | 262 | 2001 |
| Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery M Schnurr, Q Chen, A Shin, W Chen, T Toy, C Jenderek, S Green, ... Blood 105 (6), 2465-2472, 2005 | 254 | 2005 |
| The regulatory T cell–associated transcription factor FoxP3 is expressed by tumor cells LM Ebert, BS Tan, J Browning, S Svobodova, SE Russell, N Kirkpatrick, ... Cancer research 68 (8), 3001-3009, 2008 | 248 | 2008 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 235 | 2022 |
Martin StocklerNHMRC Clinical Trials Centre, University of SydneyE-mail megerősítve itt: sydney.edu.au